Article info

Download PDFPDF

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours

Authors

  1. Correspondence to Dr Walter Fiedler; fiedler{at}uke.uni-hamburg.de
View Full Text

Citation

Fiedler W, Stoeger H, Perotti A, et al
Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours

Publication history

  • Received April 19, 2018
  • Revised May 21, 2018
  • Accepted May 23, 2018
  • First published June 23, 2018.
Online issue publication 
June 23, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.